{"id":340480,"date":"2026-11-05T13:21:04","date_gmt":"2026-11-05T07:51:04","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=340480"},"modified":"2026-11-05T13:21:04","modified_gmt":"2026-11-05T07:51:04","slug":"diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list\/","title":{"rendered":"3 Diagnostics Chain, Integrated Power Utility and Branded Generic Medicines Company Stocks With a Strong Future Roadmap: Vijaya Diagnostic Centre, Torrent Power and Caplin Point Laboratories"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Vijaya Diagnostic Centre, Torrent Power and Caplin Point Laboratories: ROE of 12.7% to 18.1% and FY22 to FY26 revenue CAGR of 15.1% to 19.2%. Prices as of 4 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three diagnostics, power utility and generics stocks to watch are Vijaya Diagnostic Centre, Torrent Power and Caplin Point Laboratories. Their return on equity ranges from 12.7% to 18.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.1% to 19.2%. Vijaya Diagnostic Centre has the highest return on equity at 18.1%, while Torrent Power has the fastest revenue growth at 19.2% a year. Prices are based on the 4 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Diagnostics, power utility and generics stocks let investors follow companies that serve a growing part of the Indian economy. Vijaya Diagnostic Centre, Torrent Power and Caplin Point Laboratories cover a diagnostics chain, an integrated power utility and a branded generic medicines company.<\/p>\n<p>This list covers three diagnostics, power utility and generics stocks with complete current figures: Vijaya Diagnostic Centre, Torrent Power and Caplin Point Laboratories. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list\/#What_Are_Diagnostics_Power_Utility_and_Generics_Stocks\" title=\"What Are Diagnostics, Power Utility and Generics Stocks?\">What Are Diagnostics, Power Utility and Generics Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list\/#Diagnostics_Power_Utility_and_Generics_Stocks_at_a_Glance\" title=\"Diagnostics, Power Utility and Generics Stocks at a Glance\">Diagnostics, Power Utility and Generics Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list\/#Why_Do_Diagnostics_Power_Utility_and_Generics_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Diagnostics, Power Utility and Generics Stocks Have a Strong Roadmap in India?\">Why Do Diagnostics, Power Utility and Generics Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list\/#Why_Vijaya_Diagnostic_Centre_Features_Among_These_Diagnostics_Power_Utility_and_Generics_Stocks\" title=\"Why Vijaya Diagnostic Centre Features Among These Diagnostics, Power Utility and Generics Stocks\">Why Vijaya Diagnostic Centre Features Among These Diagnostics, Power Utility and Generics Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list\/#Why_Torrent_Power_Features_Among_These_Diagnostics_Power_Utility_and_Generics_Stocks\" title=\"Why Torrent Power Features Among These Diagnostics, Power Utility and Generics Stocks\">Why Torrent Power Features Among These Diagnostics, Power Utility and Generics Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list\/#Why_Caplin_Point_Laboratories_Features_Among_These_Diagnostics_Power_Utility_and_Generics_Stocks\" title=\"Why Caplin Point Laboratories Features Among These Diagnostics, Power Utility and Generics Stocks\">Why Caplin Point Laboratories Features Among These Diagnostics, Power Utility and Generics Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list\/#Vijaya_Diagnostic_Centre_vs_Torrent_Power_vs_Caplin_Point_Laboratories_on_Key_Financials\" title=\"Vijaya Diagnostic Centre vs Torrent Power vs Caplin Point Laboratories on Key Financials\">Vijaya Diagnostic Centre vs Torrent Power vs Caplin Point Laboratories on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list\/#Key_Risks_to_Check_Before_Investing_in_Diagnostics_Power_Utility_and_Generics_Stocks\" title=\"Key Risks to Check Before Investing in Diagnostics, Power Utility and Generics Stocks\">Key Risks to Check Before Investing in Diagnostics, Power Utility and Generics Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list\/#Final_Thoughts_on_Diagnostics_Power_Utility_and_Generics_Stocks\" title=\"Final Thoughts on Diagnostics, Power Utility and Generics Stocks\">Final Thoughts on Diagnostics, Power Utility and Generics Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list\/#What_are_diagnostics_power_utility_and_generics_stocks\" title=\"What are diagnostics, power utility and generics stocks?\">What are diagnostics, power utility and generics stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list\/#Which_diagnostics_power_utility_and_generics_stocks_are_covered_in_this_list\" title=\"Which diagnostics, power utility and generics stocks are covered in this list?\">Which diagnostics, power utility and generics stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list\/#Why_do_diagnostics_power_utility_and_generics_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do diagnostics, power utility and generics stocks have a strong future roadmap in India?\">Why do diagnostics, power utility and generics stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list\/#How_has_Vijaya_Diagnostic_Centre_performed_financially\" title=\"How has Vijaya Diagnostic Centre performed financially?\">How has Vijaya Diagnostic Centre performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list\/#How_has_Torrent_Power_performed_financially\" title=\"How has Torrent Power performed financially?\">How has Torrent Power performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list\/#How_has_Caplin_Point_Laboratories_performed_financially\" title=\"How has Caplin Point Laboratories performed financially?\">How has Caplin Point Laboratories performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list\/#What_risks_should_investors_check_before_buying_diagnostics_power_utility_and_generics_stocks\" title=\"What risks should investors check before buying diagnostics, power utility and generics stocks?\">What risks should investors check before buying diagnostics, power utility and generics stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/diagnostics-chain-integrated-power-utility-and-branded-generic-medicines-company-stocks-roadmap-lookout-list\/#Is_this_list_of_diagnostics_power_utility_and_generics_stocks_investment_advice\" title=\"Is this list of diagnostics, power utility and generics stocks investment advice?\">Is this list of diagnostics, power utility and generics stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Diagnostics_Power_Utility_and_Generics_Stocks\"><\/span><strong>What Are Diagnostics, Power Utility and Generics Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Diagnostics, power utility and generics stocks are listed companies that run diagnostic centres with pathology and radiology services, generate and distribute electricity in Gujarat and beyond, and sell branded generic medicines in Latin America and other markets. Their earnings depend on test volumes, power demand and prescriptions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Diagnostics_Power_Utility_and_Generics_Stocks_at_a_Glance\"><\/span><strong>Diagnostics, Power Utility and Generics Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/vijaya\/vijaya-diagnostic-centre-ltd-share-price-today\">Vijaya Diagnostic Centre<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,424.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14,066<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">75.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.44<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/torntpower\/torrent-power-ltd-share-price-today\">Torrent Power<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,234.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">60,947<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">25.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">21.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.73<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/caplipoint\/caplin-point-laboratories-ltd-share-price-today\">Caplin Point Laboratories<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,416.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17,194<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">25.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.00<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Caplin Point Laboratories trades at a P\/E below the industry P\/E, while Vijaya Diagnostic Centre and Torrent Power trade above it, which reflects the growth the market already expects. Readers comparing diagnostics, power utility and generics stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in diagnostics, power utility and generics stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Diagnostics_Power_Utility_and_Generics_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Diagnostics, Power Utility and Generics Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Diagnostics, power utility and generics stocks have a strong roadmap in India because growing health testing, rising power consumption and steady demand for branded generics keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Diagnostics.<\/strong> More people take regular tests.<\/li>\n<li><strong>Power utility.<\/strong> Cities and factories use more electricity.<\/li>\n<li><strong>Branded generics.<\/strong> Emerging markets buy trusted medicines.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Vijaya_Diagnostic_Centre_Features_Among_These_Diagnostics_Power_Utility_and_Generics_Stocks\"><\/span><strong>Why Vijaya Diagnostic Centre Features Among These Diagnostics, Power Utility and Generics Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the diagnostics, power utility and generics stocks on this list, Vijaya Diagnostic Centre is a Hyderabad-headquartered diagnostics chain that offers pathology and radiology services through a network of centres, with Hyderabad and Telangana as its home base.<\/p>\n<p>The company has a return on equity of 18.1%, a debt to equity ratio of 0.44 and a market capitalisation of Rs 14,066 crore. The stock trades at a P\/E of 75.0, above the industry P\/E of 59.6.<\/p>\n<p>Revenue rose from Rs 475 crore in FY22 to Rs 835 crore in FY26, a compound annual growth rate of 15.1%. Net profit grew from Rs 111 crore in FY22 to Rs 173 crore in FY26, which works out to a compound annual growth rate of 11.8%. In the June 2026 quarter, revenue grew 22.8% year on year to Rs 240 crore, while net profit rose 37.6% to Rs 53.1 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The plan is to deepen its network in existing clusters and extend the Vijaya brand into new regions, adding imaging modalities and wellness packages that raise revenue per patient. Diagnostics is a fragmented business, so organised chains with strong brands keep gaining share.<\/p>\n<p><strong>What to watch:<\/strong> Check the revenue contribution from newer regions and the pace at which new centres turn profitable.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Torrent_Power_Features_Among_These_Diagnostics_Power_Utility_and_Generics_Stocks\"><\/span><strong>Why Torrent Power Features Among These Diagnostics, Power Utility and Generics Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the health, electricity and pharma shares on this list, Torrent Power is an integrated power company in Gujarat that generates, transmits and distributes electricity, with operations in Ahmedabad, Surat and Bhiwandi, and a growing renewable energy portfolio.<\/p>\n<p>Revenue rose from Rs 14,493 crore in FY22 to Rs 29,289 crore in FY26, a compound annual growth rate of 19.2%. Net profit grew from Rs 459 crore in FY22 to Rs 2,469 crore in FY26, which works out to a compound annual growth rate of 52.3%.<\/p>\n<p>In the June 2026 quarter, revenue grew 2.4% year on year to Rs 8,205 crore. The company has a return on equity of 12.7%, a debt to equity ratio of 0.73 and a market capitalisation of Rs 60,947 crore. The stock trades at a P\/E of 25.5, above the industry P\/E of 21.8.<\/p>\n<p><strong>Roadmap:<\/strong> The company operates a stable distribution franchise and is adding large renewable capacity alongside new thermal and pumped storage projects. Its distribution licences in major cities provide steady cash flows that support these investments.<\/p>\n<p><strong>What to watch:<\/strong> Monitor renewable capacity commissioning and the progress of new generation projects.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Caplin_Point_Laboratories_Features_Among_These_Diagnostics_Power_Utility_and_Generics_Stocks\"><\/span><strong>Why Caplin Point Laboratories Features Among These Diagnostics, Power Utility and Generics Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Caplin Point Laboratories, based in Chennai, sells branded generic medicines in Latin America and other emerging markets and has built a regulated-market business through its sterile injectables arm.<\/p>\n<p>In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore. Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%.<\/p>\n<p>Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%. The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P\/E of 25.4, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.<\/p>\n<p><strong>What to watch:<\/strong> Follow new US product approvals and currency trends in Latin American markets.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Vijaya_Diagnostic_Centre_vs_Torrent_Power_vs_Caplin_Point_Laboratories_on_Key_Financials\"><\/span><strong>Vijaya Diagnostic Centre vs Torrent Power vs Caplin Point Laboratories on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three diagnostics, power utility and generics stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Vijaya Diagnostic Centre<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">475<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">835<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">173<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.7%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Torrent Power<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14,493<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">29,289<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.2%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,469<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.4%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Caplin Point Laboratories<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,308<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,303<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.2%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">650<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">28.2%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Vijaya Diagnostic Centre posts the highest return on equity in this group at 18.1%. Torrent Power combines the largest FY26 revenue at Rs 29,289 crore with the fastest revenue growth, a 19.2% compound annual rate. A useful habit with diagnostics, power utility and generics stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several pathology, Gujarat power and branded generic stocks instead of one name, which keeps a single result from deciding the outcome.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Vijaya Diagnostic Centre<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">195<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">240<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Torrent Power<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8,011<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8,205<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2.4%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Caplin Point Laboratories<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">533<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">644<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.7%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Diagnostics_Power_Utility_and_Generics_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Diagnostics, Power Utility and Generics Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these diagnostics, power utility and generics stocks, the main points are: Long-term health, electricity and pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Test volumes.<\/strong> Footfall and test mix can vary with seasons.<\/li>\n<li><strong>Component costs.<\/strong> Copper, chips and other inputs can move margins.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter diagnostics, power utility and generics stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Diagnostics_Power_Utility_and_Generics_Stocks\"><\/span><strong>Final Thoughts on Diagnostics, Power Utility and Generics Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Diagnostics, power utility and generics stocks reward investors who follow demand trends, order books and margins together. Vijaya Diagnostic Centre, Torrent Power and Caplin Point Laboratories each have a clear plan to grow. Based on the 4 November 2026 close, Vijaya Diagnostic Centre trades at Rs 1,424.6, Torrent Power at Rs 1,234.4 and Caplin Point Laboratories at Rs 2,416.1. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these diagnostics, power utility and generics stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track diagnostics, power utility and generics stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_diagnostics_power_utility_and_generics_stocks\"><\/span><strong>What are diagnostics, power utility and generics stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Diagnostics, power utility and generics stocks are listed companies that run diagnostic centres with pathology and radiology services, generate and distribute electricity in Gujarat and beyond, and sell branded generic medicines in Latin America and other markets. Their earnings depend on test volumes, power demand and prescriptions. This list looks at three of them, Vijaya Diagnostic Centre, Torrent Power and Caplin Point Laboratories, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_diagnostics_power_utility_and_generics_stocks_are_covered_in_this_list\"><\/span><strong>Which diagnostics, power utility and generics stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Vijaya Diagnostic Centre, Torrent Power and Caplin Point Laboratories. Based on the 4 November 2026 close, Vijaya Diagnostic Centre traded at Rs 1,424.6, Torrent Power at Rs 1,234.4 and Caplin Point Laboratories at Rs 2,416.1. Their return on equity ranges from 12.7% to 18.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.1% to 19.2%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_diagnostics_power_utility_and_generics_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do diagnostics, power utility and generics stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Diagnostics, power utility and generics stocks have a strong roadmap in India because growing health testing, rising power consumption and steady demand for branded generics keep widening the market for these companies. The main drivers are as follows. Diagnostics. More people take regular tests. Power utility. Cities and factories use more electricity. Branded generics. Emerging markets buy trusted medicines. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Vijaya_Diagnostic_Centre_performed_financially\"><\/span><strong>How has Vijaya Diagnostic Centre performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 475 crore in FY22 to Rs 835 crore in FY26, a compound annual growth rate of 15.1%. Net profit grew from Rs 111 crore in FY22 to Rs 173 crore in FY26, which works out to a compound annual growth rate of 11.8%. In the June 2026 quarter, revenue grew 22.8% year on year to Rs 240 crore, while net profit rose 37.6% to Rs 53.1 crore. The company has a return on equity of 18.1%, a debt to equity ratio of 0.44 and a market capitalisation of Rs 14,066 crore. The stock trades at a P\/E of 75.0, above the industry P\/E of 59.6. Looking ahead, the plan is to deepen its network in existing clusters and extend the Vijaya brand into new regions, adding imaging modalities and wellness packages that raise revenue per patient. Diagnostics is a fragmented business, so organised chains with strong brands keep gaining share.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Torrent_Power_performed_financially\"><\/span><strong>How has Torrent Power performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 14,493 crore in FY22 to Rs 29,289 crore in FY26, a compound annual growth rate of 19.2%. Net profit grew from Rs 459 crore in FY22 to Rs 2,469 crore in FY26, which works out to a compound annual growth rate of 52.3%. In the June 2026 quarter, revenue grew 2.4% year on year to Rs 8,205 crore. The company has a return on equity of 12.7%, a debt to equity ratio of 0.73 and a market capitalisation of Rs 60,947 crore. The stock trades at a P\/E of 25.5, above the industry P\/E of 21.8. Looking ahead, the company operates a stable distribution franchise and is adding large renewable capacity alongside new thermal and pumped storage projects. Its distribution licences in major cities provide steady cash flows that support these investments.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Caplin_Point_Laboratories_performed_financially\"><\/span><strong>How has Caplin Point Laboratories performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%. In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P\/E of 25.4, below the industry P\/E of 36.0. Looking ahead, the company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_diagnostics_power_utility_and_generics_stocks\"><\/span><strong>What risks should investors check before buying diagnostics, power utility and generics stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying diagnostics, power utility and generics stocks. Test volumes. Footfall and test mix can vary with seasons. Component costs. Copper, chips and other inputs can move margins. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_diagnostics_power_utility_and_generics_stocks_investment_advice\"><\/span><strong>Is this list of diagnostics, power utility and generics stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are diagnostics, power utility and generics stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Diagnostics, power utility and generics stocks are listed companies that run diagnostic centres with pathology and radiology services, generate and distribute electricity in Gujarat and beyond, and sell branded generic medicines in Latin America and other markets. Their earnings depend on test volumes, power demand and prescriptions. This list looks at three of them, Vijaya Diagnostic Centre, Torrent Power and Caplin Point Laboratories, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which diagnostics, power utility and generics stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Vijaya Diagnostic Centre, Torrent Power and Caplin Point Laboratories. Based on the 4 November 2026 close, Vijaya Diagnostic Centre traded at Rs 1,424.6, Torrent Power at Rs 1,234.4 and Caplin Point Laboratories at Rs 2,416.1. Their return on equity ranges from 12.7% to 18.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.1% to 19.2%.\"}},{\"@type\":\"Question\",\"name\":\"Why do diagnostics, power utility and generics stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Diagnostics, power utility and generics stocks have a strong roadmap in India because growing health testing, rising power consumption and steady demand for branded generics keep widening the market for these companies. The main drivers are as follows. Diagnostics. More people take regular tests. Power utility. Cities and factories use more electricity. Branded generics. Emerging markets buy trusted medicines. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Vijaya Diagnostic Centre performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 475 crore in FY22 to Rs 835 crore in FY26, a compound annual growth rate of 15.1%. Net profit grew from Rs 111 crore in FY22 to Rs 173 crore in FY26, which works out to a compound annual growth rate of 11.8%. In the June 2026 quarter, revenue grew 22.8% year on year to Rs 240 crore, while net profit rose 37.6% to Rs 53.1 crore. The company has a return on equity of 18.1%, a debt to equity ratio of 0.44 and a market capitalisation of Rs 14,066 crore. The stock trades at a P\/E of 75.0, above the industry P\/E of 59.6. Looking ahead, the plan is to deepen its network in existing clusters and extend the Vijaya brand into new regions, adding imaging modalities and wellness packages that raise revenue per patient. Diagnostics is a fragmented business, so organised chains with strong brands keep gaining share.\"}},{\"@type\":\"Question\",\"name\":\"How has Torrent Power performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 14,493 crore in FY22 to Rs 29,289 crore in FY26, a compound annual growth rate of 19.2%. Net profit grew from Rs 459 crore in FY22 to Rs 2,469 crore in FY26, which works out to a compound annual growth rate of 52.3%. In the June 2026 quarter, revenue grew 2.4% year on year to Rs 8,205 crore. The company has a return on equity of 12.7%, a debt to equity ratio of 0.73 and a market capitalisation of Rs 60,947 crore. The stock trades at a P\/E of 25.5, above the industry P\/E of 21.8. Looking ahead, the company operates a stable distribution franchise and is adding large renewable capacity alongside new thermal and pumped storage projects. Its distribution licences in major cities provide steady cash flows that support these investments.\"}},{\"@type\":\"Question\",\"name\":\"How has Caplin Point Laboratories performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%. In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P\/E of 25.4, below the industry P\/E of 36.0. Looking ahead, the company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying diagnostics, power utility and generics stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying diagnostics, power utility and generics stocks. Test volumes. Footfall and test mix can vary with seasons. Component costs. Copper, chips and other inputs can move margins. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of diagnostics, power utility and generics stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Diagnostics, Power Utility and Generics Stocks with a strong future roadmap: Vijaya Diagnostic Centre, Torrent Power and Caplin Point Laboratories. Compare price, valuation, return on equity and revenue growth as of 4 November 2026.<\/p>\n","protected":false},"author":29,"featured_media":340479,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,9565,6920,20629,20630,20311,19802,20628,7782,8585],"class_list":["post-340480","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-caplin-point-laboratories","tag-diagnostics","tag-electricity-and-pharma-shares","tag-gujarat-power-and-branded-generic-stocks","tag-health","tag-pathology","tag-power-utility-and-generics-stocks","tag-torrent-power","tag-vijaya-diagnostic-centre"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["340479"],"rank_math_title":["Diagnostics, Power Utility and Generics Stocks"],"rank_math_description":["Compare 3 diagnostics, power utility and generics stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 4 Nov 2026."],"rank_math_focus_keyword":["diagnostics, power utility and generics stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-diagnostics-chain-integrated-power-utility-and-branded-generic-medicines.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=340480"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340480\/revisions"}],"predecessor-version":[{"id":340481,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340480\/revisions\/340481"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/340479"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=340480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=340480"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=340480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}